RU94036773A - Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i - Google Patents

Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i

Info

Publication number
RU94036773A
RU94036773A RU94036773/13A RU94036773A RU94036773A RU 94036773 A RU94036773 A RU 94036773A RU 94036773/13 A RU94036773/13 A RU 94036773/13A RU 94036773 A RU94036773 A RU 94036773A RU 94036773 A RU94036773 A RU 94036773A
Authority
RU
Russia
Prior art keywords
phe
cys
amino acid
glu
domain
Prior art date
Application number
RU94036773/13A
Other languages
Russian (ru)
Inventor
Норрис Фанни
Dk]
Норрис Келль
Эрик Бьерн Серен
Кристиан Петерсен Ларс
Вильстед Ольсен Оле
Original Assignee
Ново Нордиск А/С (DK)
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С (DK), Ново Нордиск А/С filed Critical Ново Нордиск А/С (DK)
Priority to RU94036770/13A priority Critical patent/RU94036770A/en
Publication of RU94036773A publication Critical patent/RU94036773A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

FIELD: biochemistry, molecular biology. SUBSTANCE: variant of domain I of human protease inhibitor of Kunitz type has the following amino acid sequence: X-Cys-Ala- -Phe-Lys-Ala-Asp-X-Gly-X-Cys-X, X, X, X, X, X-Phe-Phe-Phe-Asn-Ile-Phe- -Thr-Arg-Glu-Cys-Glu-Glu-Phe-X-Tyr-Gly-Gly-Cys-X, X, X-Gln-Asn- -Arg-Phe-X-Ser-Leu-Glu-Glu-Cys-X, X-Met-Cys-Thr-Arg-X(sequence D N1) where Xmeans H or 1-7 natural amino acid residues for exception Cys; every of X-Xindependently means natural amino acid residue and Xmeans OH or 1-5 natural amino acid residues for exception Cys; condition: at least one of amino acid residues X-Xdistincts of the corresponding amino acid residue of natural sequence. EFFECT: improved method of inhibitor preparing.

Claims (1)

Вариант домена 1 ингибитора протеазы человека типа Кунитца, а именно ингибитора метаболизма тканевого фактора (TFP1), где указанный вариант содержит следующую аминокислотную последовательность: Х1, Суs, Аlа, Phe, Lуs, Аlа, Аsр, Х2, Gly, Х3, Суs, Х4, Х5, Х6, Х7, Х8, Х9, Phe, Phe, Phe, Asn, Ile, Phe, Thr, Arg, Gln, Cys, Glu, Glu, Phe, X10, Туr, Gly, Gly, Cys, X11, X12, X13, Gln, Asn, Arg, Phe, X14, Ser, Leu, Glu, Glu, Cys, X15, X16, Met, Cys, Thr, Arg, X17 (SEQ D N 1), где Х1 - Н или 1 - 7 натуральных аминокислотных остатков, за исключением Суs; каждый из Х2 - Х16 - независимо натуральный аминокислотный остаток, а Х17 - OH или 1 - 5 натуральных аминокислотных остатков, за исключением Суs; при условии, что по крайней мере один из аминокислотных остатков Х1 - Х17 отличается от соответствующего аминокислотного остатка нативной последовательности.A variant of domain 1 of a Kunitz-type human protease inhibitor, namely a tissue factor metabolism inhibitor (TFP1), wherein said variant contains the following amino acid sequence: X 1 , Cs, Ala, Phe, Ls, Ala, Asp, X 2 , Gly, X 3 , Sous, X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , Phe, Phe, Phe, Asn, Ile, Phe, Thr, Arg, Gln, Cys, Glu, Glu, Phe, X 10 , Tur , Gly, Gly, Cys, X 11 , X 12 , X 13 , Gln, Asn, Arg, Phe, X 14 , Ser, Leu, Glu, Glu, Cys, X 15 , X 16 , Met, Cys, Thr, Arg , X 17 (SEQ DN 1), where X 1 is H or 1 to 7 natural amino acid residues, with the exception of Cs; each of X 2 - X 16 is independently a natural amino acid residue, and X 17 is OH or 1 to 5 natural amino acid residues, with the exception of Sus; provided that at least one of the amino acid residues X 1 - X 17 is different from the corresponding amino acid residue of the native sequence.
RU94036773/13A 1992-01-07 1993-01-07 Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i RU94036773A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94036770/13A RU94036770A (en) 1992-01-07 1993-01-07 Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK9200002 1992-01-07
DKDK92/00002 1992-01-07
DKDK92/00340 1992-11-16
DK9200340 1992-11-16

Publications (1)

Publication Number Publication Date
RU94036773A true RU94036773A (en) 1996-09-27

Family

ID=26068350

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94036773/13A RU94036773A (en) 1992-01-07 1993-01-07 Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i

Country Status (13)

Country Link
EP (1) EP0621872A1 (en)
JP (1) JPH07504891A (en)
AU (1) AU675926B2 (en)
CA (1) CA2127246A1 (en)
CZ (1) CZ164494A3 (en)
FI (1) FI943234A (en)
HU (1) HUT70293A (en)
IL (1) IL104324A0 (en)
NO (1) NO942549L (en)
NZ (1) NZ246570A (en)
RU (1) RU94036773A (en)
WO (1) WO1993014122A1 (en)
ZA (1) ZA9396B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ATE529444T1 (en) * 1994-01-11 2011-11-15 Dyax Corp HUMAN PLASMIN INHIBITORS DERIVED FROM THE KUNITZ DOMAINS
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (en) * 1994-08-05 2003-02-20 Chiron Corp PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
AU708394B2 (en) * 1995-06-07 1999-08-05 Novartis Vaccines And Diagnostics, Inc. Regulation of cytokine synthesis and release
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
AU5736899A (en) * 1998-08-25 2000-03-14 Knut Kleesiek A mutant of tissue factor pathway inhibitor, dna sequence and use for detecting thrombotic disorders
CN1325889A (en) * 2000-05-26 2001-12-12 上海博德基因开发有限公司 Polypeptide-human kazal-type inhibitor 11 and polynucleotide for coding it
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2311432E (en) 2002-06-07 2015-02-09 Dyax Corp Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
DK1542710T3 (en) * 2002-08-28 2012-10-15 Dyax Corp Method of preserving organs and tissues
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021557A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
ES2773766T3 (en) 2008-12-19 2020-07-14 Baxalta GmbH TFPI inhibitors and methods of use
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
LT2521568T (en) 2010-01-06 2018-12-10 Dyax Corp. Plasma kallikrein binding proteins
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CN105713092B (en) 2011-01-06 2019-09-10 戴埃克斯有限公司 Blood plasma prekallikrein binding protein
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (en) * 1989-08-18 1989-08-18 Novo Nordisk As PROTEINS

Also Published As

Publication number Publication date
HU9401990D0 (en) 1994-09-28
AU3346093A (en) 1993-08-03
ZA9396B (en) 1993-08-10
EP0621872A1 (en) 1994-11-02
JPH07504891A (en) 1995-06-01
WO1993014122A1 (en) 1993-07-22
NZ246570A (en) 1996-09-25
IL104324A0 (en) 1993-05-13
NO942549D0 (en) 1994-07-06
AU675926B2 (en) 1997-02-27
CA2127246A1 (en) 1993-07-22
FI943234A0 (en) 1994-07-06
FI943234A (en) 1994-07-06
NO942549L (en) 1994-09-07
CZ164494A3 (en) 1994-12-15
HUT70293A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
RU94036773A (en) Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i
Mutt et al. Structure of the Porcine Vasoactive Intestinal Octacosapeptide: The Amino‐Acid Sequence. Use of Kallikrein in Its Determination
Püschel et al. Isolation and characterization of dipeptidyl peptidase IV from human placenta
KR940703860A (en) Novel human Kunizin protease inhibitors and variants thereof (A NOVEL HUMAN KUNITZ-TYPE PROTEASE INHIBITOR AND VARIANTS THEREOF)
NL300013I2 (en) New proteins with TNF inhibitory effect and their preparation.
RU94045952A (en) Domain of protease inhibitor, dna, vector, cell, method of preparing protease inhibitor, pharmaceutical composition, use of domain
KR940703854A (en) A human kunitz-type protease inhibitor variant
RU94036776A (en) Domain of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of protease inhibitor domain
DK165988B (en) MODIFIED EGLINES B AND C, THEIR USE AS PROTEASE INHIBITORS, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE MODIFIED EGLINES B AND C
MD1652G2 (en) Protein possessing the cytokin - type activity, recombinant DNA-codifyer for such protein, transformed cells and microorganism, expression vector, process for protein obtaining and remedy containing such a protein
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
AU531556B2 (en) Tripeptides
Fisher et al. R2 C-terminal peptide inhibition of mammalian and yeast ribonucleotide reductase
Ramage et al. Solid phase peptide synthesis of ubiquitin
US6096864A (en) Peptides for use in wound treatment
Kuromizu et al. Reexamination of the primary structure of an antitumor protein, neocarzinostatin
Radhakrishna et al. Purification and characterization of an N-acylaminoacyl-peptide hydrolase from rabbit muscle
US5136023A (en) Polypeptide with cell-spreading activity
DK0918795T3 (en) Antiangiogenic drugs for the treatment of cancer, arthritis and retinopathy
Okada et al. Synthesis of peptide fragments related to eglin c and examination of their inhibitory effect on human leukocyte elastase, cathepsin G and α-chymotrypsin
KR890014735A (en) Modified protein
RU94036770A (en) Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use
Lengweiler et al. Elucidation of the disulfide-bonding pattern in the factor I modules of the sixth component (C6) of human complement
KNORR et al. [B17-D-Leucine] Insulin and [B17-Norleucine] Insulin: synthesis and biological properties
Okada et al. Amino acids and peptides. Part 32. Total synthesis of eglin c. Part 2. Synthesis of a heptacontapeptide corresponding to the entire amino acid sequence of eglin c and of related peptides, and studies on the relationship between the structure and inhibitory activity against human leukocyte elastase, cathepsin G and α-chymotrypsin